GBA1 and melanoma: Supporting this clinical observation, studies in a type 1 GD mouse model carrying the homozygous point mutation (Gba1 D409V/D409V) demonstrated that subcutaneous injection of murine melanoma cells (B16F10) led to markedly increased tumor growth and weight compared with control littermates [177].